Study guide
13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones
Key Takeaways Explain This Topic AI
ICH E9 section 4.5 defines an interim analysis as any analysis intended to compare treatment arms with respect to efficacy or safety before formal completion of the trial.
Every interim analysis must be planned in advance and described in the protocol, and the procedures selected must always ensure the overall probability of type I error is controlled.
ICH E9 states that boundaries for stopping on efficacy are generally more conservative — requiring more evidence — than boundaries for stopping on safety.
Execution of an interim analysis is a completely confidential process; investigators are told only the decision to continue, discontinue or modify the trial, never the interim results.
ICH E6(R3) Annex 1 section 3.9.9 requires committees that could affect participant safety or result reliability to have relevant expertise, managed conflicts of interest, written charters and documented decisions.
Last updated: August 2026
Interim Analyses, DSMB/IDMC Oversight & Evaluation Milestones
Quick Reference: ICH E9 section 4.5 defines an interim analysis as "any analysis intended to compare treatment arms with respect to efficacy or safety at any time prior to formal completion of a trial." The word that carries the weight is compare . Counting how many participants have enrolled is not an interim analysis. Comparing outcomes between arms is — even if nobody intended to act on it.
Why this is tested
The ACRP-CP Exam Content Outline lists 2H, "Efficacy and safety evaluation milestones (e.g., interim analysis result, DSMB review)" as a Domain 2 knowledge statement. It is a domain where site-based professionals are asked to reason about something they never see directly, which is exactly why it generates good exam items.
Why unplanned looks are dangerous
Each time you test accumulating data for a statistically significant difference, you take another chance of a false positive. With a conventional two-sided significance level of 0.05, a single analysis has a 5% chance of a spurious "significant" result under the null hypothesis. Repeat the test at five interim points without adjustment and the overall type I error rate rises to roughly 14% — you have almost tripled the false-positive risk without adding a single participant.
ICH E9 is explicit: "The procedures selected should always ensure that the overall probability of type I error is controlled."
Alpha spending
The solution is to treat the total significance level as a budget spent across the planned looks:
Approach Behaviour Consequence
O'Brien–Fleming Very stringent early boundaries, relaxing towards the end Early stopping requires an overwhelming effect; the final analysis keeps a critical value close to the unadjusted one
Pocock Equal, constant boundary at every look Easier to stop early, but a meaningfully stricter final-analysis threshold
Flexible alpha spending function Alpha spent as a function of information accrued; number and timing of looks need not be fixed in advance Operationally practical for event-driven trials
Exam Watchout: O'Brien–Fleming is the common default in confirmatory trials precisely because it protects the final analysis. If a trial stops early under an O'Brien–Fleming boundary, the effect observed was extreme, and the estimate of effect size at early stopping is typically biased upward — a nuance regulators and journals both scrutinise.
The asymmetry between efficacy and safety
ICH E9 states that "boundaries for monitoring efficacy require more evidence to terminate a trial early (i.e. they are more conservative) than boundaries for monitoring safety."
The ethical logic is straightforward: stopping early for harm protects participants who would otherwise be exposed, so a lower evidential bar is appropriate. Stopping early for benefit risks declaring a treatment effective on the basis of a random high, so the bar is set higher.
Reasons a trial may stop early
- Reason Trigger
- Overwhelming efficacy Superiority clearly established at a pre-specified boundary
- Harm Unacceptable adverse effects; unfavourable benefit–risk
Futility Demonstration of a relevant treatment difference has become unlikely; continuing would expose participants for no realistic gain
- External evidence Another trial or a regulatory action changes the equipoise
- Operational failure Recruitment or data quality so poor the trial cannot answer its question
ICH E9 tempers all of this: most trials intended to support efficacy and safety "should proceed to full completion of planned sample size accrual; trials should be stopped early only for ethical reasons or if the power is no longer acceptable."
The independent data monitoring committee
ICH E9 section 4.6 covers the body variously called the Independent Data Monitoring Committee (IDMC) , Data and Safety Monitoring Board (DSMB) or Data Monitoring Committee (DMC) . The names are interchangeable; the function is not.
What it is and is not
It is It is not
Established by the sponsor, but independent of the sponsor's trial team and of the investigators The IRB/IEC — which reviews ethics and approves the protocol, and does not see unblinded comparative data
The only group that routinely reviews unblinded comparative efficacy and safety data during the trial A decision-maker — it recommends ; the sponsor decides and is accountable
Governed by a charter agreed before the first review An endpoint adjudication committee, which classifies events while remaining blinded
Composition and governance
ICH E6(R3) Annex 1 section 3.9.9 states that committees established for purposes that could impact participant safety or the reliability of trial results "should include members with relevant expertise and with managed conflicts of interest, have written operating procedures (e.g., charters) and document their decisions."
Typical membership: two or more clinicians with expertise in the therapeutic area, plus at least one independent statistician . Members must have no financial or professional stake in the outcome — no equity, no consultancy with the sponsor on the product, no participation as an investigator in the trial.
The charter
A DSMB/IDMC charter defines, before the first meeting:
- Membership, independence criteria and conflict-of-interest management
- The schedule of reviews — calendar-driven, enrolment-driven or event-driven
- Exactly what data each review covers and in what format
- Stopping guidelines and the statistical monitoring boundaries
- Voting rules, quorum and how recommendations are communicated
- Meeting structure and record keeping
Open and closed sessions OPEN session Sponsor representatives and sometimes investigators may attend.
Blinded, pooled information only: enrolment, protocol deviations,
data completeness, overall (not by-arm) event rates.
│
CLOSED session IDMC members and the unblinded (independent) statistician only.
Full unblinded comparative efficacy and safety data by treatment arm.
- │
- EXECUTIVE session IDMC voting members alone. Deliberation and formulation of the
recommendation.
│
RECOMMENDATION To the sponsor, typically one of:
- "continue unchanged" · "continue with modification"
- "suspend enrolment" · "terminate"
- │
- SPONSOR DECIDES The sponsor acts, and notifies investigators, IRBs/IECs and
regulatory authorities as required.
What the site is told — and what it is not
ICH E9 is unambiguous: execution of an interim analysis "should be a completely confidential process" and "all staff involved in the conduct of the trial should remain blind to the results of such analyses" , because knowledge of interim results can change recruitment behaviour and bias treatment comparisons. "Investigators should only be informed about the decision to continue or to discontinue the trial, or to implement modifications to trial procedures."
For a coordinator or monitor, three practical consequences:
You will not be told the interim numbers , and asking is not a reasonable request.
A DSMB recommendation reaching you is a communication, not a negotiation. If enrolment is suspended, it stops that day.
Anything you learn incidentally about arm assignment or interim results is a potential unblinding event and is reported, not discussed.
Exam Watchout: An unplanned interim analysis is not simply undesirable — ICH E9 says such analyses "should be avoided" , and if one occurs the clinical study report must explain why it was necessary, the degree to which blinding had to be broken, an assessment of the potential magnitude of bias introduced, and the impact on interpretation. When circumstances genuinely require a new interim analysis, a protocol amendment describing it must be completed before unblinded access to treatment comparison data — not afterwards.
Other evaluation milestones
Dose escalation review committees in early-phase trials, which authorise progression to the next cohort against pre-specified dose-limiting toxicity rules.
Endpoint adjudication committees , which classify events such as myocardial infarction or stroke against protocol definitions while remaining blinded — distinct from an IDMC in both blinding and purpose.
Futility analyses , which may be non-binding, allowing the sponsor to continue despite crossing a futility boundary.
Sample size re-estimation , which may be performed blinded, using pooled variance, without spending alpha.
Realistic exam scenario
Scenario: A principal investigator on a large event-driven cardiovascular outcomes trial is contacted by a colleague who sits on the trial's DSMB. Over dinner the colleague mentions that the treatment arm "is doing well, you'll be pleased." The next week the PI's site screens fourteen new candidates, and the coordinator notices the PI approving two participants whose eligibility is marginal and whom he would previously have excluded.
Evaluation:
The DSMB member has committed a serious breach of confidentiality . Interim results are restricted to the closed and executive sessions precisely to prevent this.
The predicted harm has materialised immediately. ICH E9 warns that if trial staff learn interim results, "their attitudes to the trial will be modified and cause changes in the characteristics of patients to be recruited or biases in treatment comparisons." Loosened eligibility judgement is that bias in action.
This is operational bias , and it degrades the reliability of the trial's results — squarely within the ICH E6(R3) definition of noncompliance that can significantly affect the reliability of trial results.
Correct actions: the PI should report the disclosure to the sponsor immediately rather than treating it as private conversation; the two marginal enrolments should be reviewed against the eligibility criteria and any that do not meet them documented as deviations; the sponsor should treat this under Annex 1 section 3.12, performing a root cause analysis and notifying the IRB/IEC and regulatory authority if it constitutes serious noncompliance; the DSMB chair and sponsor must address the member's breach under the charter's conflict and confidentiality provisions; and the statistical team may need to assess whether data from the affected period require sensitivity analysis.